BioSpace News Archive

Genetown

/C O R R E C T I O N -- EMD Serono/

Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa‡ targeting TGF-β/PD-L1, in second-line NSCLC

May 13, 2020
·
19 min read
Genetown

iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Promising clinical research supports Xoft brain IORT as a viable treatment option forglioblastoma multiforme that may extend patients’ lives

May 13, 2020
·
11 min read
BioMidwest

Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting

Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming virtual poster presentation at the 2020 American Society of Clinical Oncology Annual Meeting, taking place from May 29-31, 2020.

May 13, 2020
·
1 min read
Drug Development

Polynoma Presenting Final Analysis of MAVIS Phase III Part B1 Data of Its Investigational Melanoma Vaccine, Seviprotimut-L, at ASCO20 Virtual Scientific Program

Study data show a durable recurrence-free survival clinical benefit in patients with localized melanoma, supporting the potential use of seviprotimut-L as an adjuvant treatment

May 13, 2020
·
11 min read
Pharm Country

Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio

Regeneron Pharmaceuticals, Inc. announced the company will share updates from its diverse clinical oncology portfolio at the 2020 American Society of Clinical Oncology Annual Meeting from May 29-31 taking place virtually.

May 13, 2020
·
18 min read
Drug Development

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT

May 13, 2020
·
8 min read
Genetown

Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

Bristol Myers Squibb and bluebird bio, Inc. announced updated results from the pivotal, Phase 2 KarMMa study evaluating the efficacy and safety of the companies’ investigational B-cell maturation antigen -directed chimeric antigen receptor T cell immunotherapy, idecabtagene vicleucel, in patients with relapsed and refractory multiple myeloma.

May 13, 2020
·
14 min read
Drug Development

Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy in Metastatic First-Line Non-Small Cell Lung Cancer Patients with PD-L1 ≥1%

Opdivo plus Yervoy continues to demonstrate sustained improvement in overall survival over chemotherapy, with 33% of patients still alive after a minimum follow-up of three years, regardless of PD-L1 status

May 13, 2020
·
32 min read
Pharm Country

New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC

First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA Plus Concurrent Chemoradiation Achieved Objective Response Rate of 67.0% and 56.6% in Two Cohorts

May 13, 2020
·
47 min read
Drug Development

Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types

Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors.

May 13, 2020
·
19 min read